soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm and in Obesity without Diabetes SOUL Trial (NEJM 2025): Oral

Experience a comfortable and relaxed atmosphere with our friendly staff, who are always available to answer your questions

Glaze-Rowe said elected officials across the country are having the debate over GLP-1s high short-term cost versus its long-term benefits

Recent blood sugar levels and hemoglobin A1c results The date you started semaglutide and any dose changes All vision symptoms, even if they seem minor or temporary Other health conditions such as high blood pressure or kidney disease Any eye treatments, injections, or laser procedures you have had Existing diabetic retinopathy calls for enhanced vigilance when starting semaglutide

Semaglutide: A Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA): Semaglutide belongs to a class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs)

Drugs to treat heart failure

Emerging preclinical work explores its potential effects on alcohol use disorder, Alzheimer's disease biomarkers, and kidney disease progression